Ignite Creation Date:
2025-12-24 @ 11:45 PM
Ignite Modification Date:
2026-02-22 @ 8:40 PM
Study NCT ID:
NCT01087151
Status:
COMPLETED
Last Update Posted:
2016-11-02
First Post:
2010-03-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
Sponsor:
Genentech, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-08
Start Date Type:
None
Primary Completion Date:
2012-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-06
Completion Date Type:
ACTUAL
First Submit Date:
2010-03-11
First Submit QC Date:
None
Study First Post Date:
2010-03-16
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2013-08-28
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2016-11-01
Last Update Post Date:
2016-11-02
Last Update Post Date Type:
ESTIMATED